Kathleen Coelingh

Title: Kathleen Coelingh: Innovator in Vaccine Development

Introduction

Kathleen Coelingh is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of vaccine development, holding 2 patents that focus on recombinant parainfluenza virus expression systems and vaccines. Her work has the potential to impact public health by advancing vaccine formulations against various pathogens.

Latest Patents

Kathleen's latest patents include innovative technologies related to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA. These inventions are designed to express heterologous gene products in suitable host cell systems. Additionally, they facilitate the rescue of negative strand RNA recombinant viruses that can express, package, and present the heterologous gene product. The chimeric viruses and expression products developed through her research may be utilized in vaccine formulations, providing solutions against a broad range of pathogens and antigens.

Career Highlights

Kathleen Coelingh has established herself as a key figure in the biotechnology sector. She is currently associated with Medimmune Limited, where she continues to innovate and contribute to vaccine research and development. Her expertise in virology and genetic engineering has positioned her as a leader in her field.

Collaborations

Kathleen has collaborated with various professionals in her field, including her coworker Aurelia Haller. Their combined efforts have led to advancements in vaccine technology and research.

Conclusion

Kathleen Coelingh's work exemplifies the importance of innovation in vaccine development. Her patents and contributions to the field are paving the way for new solutions in combating infectious diseases.